Leadership Overview
PT. Inertia Utama has 4 executives leading key functions including information technology, corporate strategy, regulatory oversight, and operational management.
Committed to advancing pharmaceutical standards, PT. Inertia Utama prioritizes rigorous research and development to improve patient health outcomes across the Indonesian market through sustainable manufacturing practices.
Committed to advancing pharmaceutical standards, PT. Inertia Utama prioritizes rigorous research and development to improve patient health outcomes across the Indonesian market through sustainable manufacturing practices.
Leadership Roles at PT. Inertia Utama
Hery Sutanto - President & Director
Hery Sutanto, the President & Director at PT. Inertia Utama, executes the overarching corporate strategy to expand pharmaceutical market presence. Sutanto oversees daily operations, ensuring that manufacturing output meets the highest quality benchmarks required for public health safety. By fostering partnerships with regional healthcare providers, the President & Director drives growth across the Indonesian archipelago. Hery Sutanto manages the allocation of capital resources to support research initiatives and facility upgrades. This leadership role requires constant collaboration with the board to refine long-term business objectives and navigate complex regulatory landscapes. Through the implementation of lean manufacturing principles, the President & Director optimizes production costs while maintaining product efficacy. Sutanto secures the financial health of the organization by identifying new revenue streams within the pharmaceutical industry. Ultimately, the President & Director maintains a focus on sustainable growth, ensuring that the company remains a reliable provider of essential medical solutions for diverse patient populations.
Raymond Tjandrawinata - President & Commissioner
Raymond Tjandrawinata, the President & Commissioner at PT. Inertia Utama, provides high-level governance and strategic oversight for all pharmaceutical development activities. Tjandrawinata monitors the alignment of corporate policies with national health regulations to ensure full compliance. By evaluating the long-term viability of research projects, the President & Commissioner guides the company toward sustainable innovation in drug manufacturing. Raymond Tjandrawinata facilitates communication between the board and executive management to maintain transparency and operational excellence. This leadership role involves assessing market trends to anticipate shifts in the pharmaceutical landscape and adjusting corporate direction accordingly. Through the promotion of rigorous scientific standards, the President & Commissioner upholds the reputation of the company as a leader in the industry. Tjandrawinata directs the evaluation of strategic investments, ensuring that all capital expenditures support the core mission of improving patient care. Ultimately, the President & Commissioner secures the future stability of the organization through prudent risk management and visionary leadership.
Wimala Widjaja - Chief Information Officer
Wimala Widjaja, the Chief Information Officer at PT. Inertia Utama, directs the digital transformation of pharmaceutical manufacturing processes. Widjaja architects secure data infrastructure to protect proprietary research while optimizing supply chain visibility across regional distribution networks. By implementing advanced analytics, the Chief Information Officer enhances production efficiency and ensures compliance with strict industry data standards. Wimala Widjaja manages the integration of automated systems within the laboratory environment to accelerate drug development cycles. This leadership role involves coordinating with technical teams to maintain robust cybersecurity protocols against evolving digital threats. Through the deployment of scalable cloud solutions, the Chief Information Officer supports the broader organizational goal of maintaining a competitive edge in the pharmaceutical sector. Widjaja drives innovation by aligning technological capabilities with the specific manufacturing requirements of the company, ultimately securing operational continuity and data integrity for all stakeholders involved in the pharmaceutical lifecycle.
Ferry Soetikno - Direktur
Ferry Soetikno, the Direktur at PT. Inertia Utama, manages the operational execution of pharmaceutical manufacturing and distribution strategies. Soetikno oversees the daily workflow of production facilities, ensuring that all processes adhere to strict quality control protocols. By coordinating logistics across regional markets, the Direktur optimizes the supply chain to guarantee the timely delivery of essential medications. Ferry Soetikno directs the implementation of safety standards within the manufacturing environment to protect personnel and product integrity. This leadership role involves managing cross-functional teams to resolve operational bottlenecks and improve overall output efficiency. Through the application of industry-specific expertise, the Direktur supports the development of new pharmaceutical products that address critical health needs. Soetikno monitors performance metrics to identify areas for continuous improvement in manufacturing throughput. Ultimately, the Direktur ensures that the operational activities of the company remain consistent with the broader strategic goals of providing high-quality pharmaceutical solutions to the public.
Explore Leadership Teams in Manufacturing
Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas. The company focuses on areas such as oncology, internal medicine, inflammation and immunology, and vaccines to help prevent, treat, and manage disease worldwide.
Company Leadership SC
SK
NA
MO
Founded in 195 and headquartered in Paris, France, Pierre Fabre is a private pharmaceuticals and dermo-cosmetics company. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader brand Eau Thermale Avène).
Company Leadership SC
ET
Ad
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership DS
NB
SS
TriRx Pharmaceuticals is a contract development and manufacturing organization specializing in both non-sterile and sterile products, including animal health injectables and packaging solutions. The company offers a wide range of capabilities such as development and analytics, sterile and non-sterile manufacturing, and packaging services. With facilities located in Huntsville, Alabama, and Segré, France, TriRx aims to support customers' commercialization efforts across global markets. Their target clients include pharmaceutical companies looking for advanced solutions to bring their products to market.
Company Leadership TT
JS
KL
RM
Frequently Asked Questions Regarding PT. Inertia Utama Top Executives and Leadership Team
